Jun 2026 (Q2 FY26) — Aug 13, 2026
Eton Pharmaceuticals Q2 FY26 — Record Revenue, Margin Expansion, and Strategic Portfolio Expansion
Read the full callEton Pharmaceuticals (ETON) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Eton Pharmaceuticals earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 37.6 | +98.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 34.0 | +41.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 11.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$51.33 −2.93% · −$1.55
Performance +173.5% 1Y
1Y: $18.77 on 14 Oct 2025 → $51.33. High $64.43 (24 Aug 2026), low $14.35 (5 Feb 2026).
- Previous close
- $52.88
- 52-week range
- $14.35 – $64.43
- One year
- +168.04%
Overview
- Symbol
- ETON
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Eton Pharmaceuticals earnings calls (ETON)
Financials
What the filings say
Net profit, year on year: +548% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 10 | 12 | 17 | 19 | 22 | 21 | 24 | 38 |
| Operating profit | 1 | 1 | -0 | -1 | -1 | 2 | 2 | 13 |
| Operating margin | 4.9% | 5.4% | −2.7% | −7.8% | −6.1% | 11.6% | 9.9% | 34.0% |
| Other income | -0 | -1 | — | — | — | — | — | — |
| Interest | 0 | — | 1 | — | 1 | — | 1 | — |
| Profit before tax | 1 | -1 | -1 | -3 | -2 | 1 | 2 | 12 |
| Tax rate | −25.1% | −17.0% | −4.9% | −2.6% | 1.4% | −4.9% | 1.3% | 1.2% |
| Net profit | 1 | -1 | -2 | -3 | -2 | 1 | 2 | 12 |
| EPS ($ per share) | 0.02 | — | -0.06 | -0.10 | -0.07 | — | 0.06 | 0.42 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -46 | -64 | -92 | -94 | -103 | -104 | -108 | -112 |
| Total liabilities | 2 | 7 | 11 | 10 | 12 | 16 | 52 | 66 |
| Fixed assets | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 28 | 17 | 26 | 27 | 25 | 32 | 76 | 92 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8 | -18 | -22 | -5 | 5 | 7 | 1 | 11 |
| Cash from investing | -0 | -2 | -0 | -3 | -3 | -1 | -40 | -0 |
| Cash from financing | 22 | 5 | 32 | 0 | -0 | -1 | 33 | 1 |
| Net cash flow | 14 | -15 | 9 | -7 | 2 | 5 | -6 | 11 |
| Capital expenditure | -0 | -1 | -0 | -0 | -0 | 0 | -0 | -0 |
| Free cash flow | -8 | -19 | -22 | -5 | 5 | 7 | 1 | 10 |
Insider filings
47 filings between Dec 12, 2025 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$25.41M
24 sales by 5 insiders
Compensation
not trading decisions- 15
- Option exercise — converted options into shares
- 7
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 option exercised.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BRYNJELSEN SEAN | — | $9.91M | Aug 20, 2026 |
| Opaleye Management Inc. | — | $5.83M | Jul 14, 2026 |
| Krempa David | — | $5.09M | Oct 6, 2026 |
| MAIER PAUL V | — | $2.95M | Aug 28, 2026 |
| Adams Jennifer McKie | — | $1.62M | Jun 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Krempa David Chief Business Officer | Sale | 4,166 | $229.4K |
| Oct 2, 2026 | Krempa David Chief Business Officer | Option exercise | 10,522 | — |
| Aug 28, 2026 | MAIER PAUL V Director | Option exercise | 50,000 | $189.0K |
| Aug 28, 2026 | MAIER PAUL V Director | Sale | 128 | $7.9K |
| Aug 28, 2026 | MAIER PAUL V Director | Option exercise | 12,500 | $91.4K |
| Aug 28, 2026 | MAIER PAUL V Director | Sale | 13,485 | $811.9K |
| Aug 28, 2026 | MAIER PAUL V Director | Sale | 36,387 | $2.13M |
| Aug 24, 2026 | Krempa David Chief Business Officer | Sale | 25,000 | $1.63M |
| Aug 24, 2026 | Krempa David Chief Business Officer | Option exercise | 25,000 | $182.8K |
| Aug 20, 2026 | BRYNJELSEN SEAN President & CEO | Sale | 7,342 | $456.1K |
| Aug 20, 2026 | BRYNJELSEN SEAN President & CEO | Sale | 36,373 | $2.22M |
| Aug 20, 2026 | BRYNJELSEN SEAN President & CEO | Sale | 47,307 | $2.85M |
| Aug 19, 2026 | BRYNJELSEN SEAN President & CEO | Sale | 8,978 | $562.5K |
| Jul 14, 2026 | Opaleye Management Inc. 10% owner | Sale | 13,315 | $499.9K |
| Jul 14, 2026 | Opaleye Management Inc. 10% owner | Sale | 15,000 | $563.1K |
| Jul 14, 2026 | BRYNJELSEN SEAN President & CEO | Option exercise | 200,000 | $274.0K |
| Jul 12, 2026 | BRYNJELSEN SEAN President & CEO | Option exercise | 27,500 | — |
| Jul 12, 2026 | Krempa David Chief Business Officer | Option exercise | 10,000 | — |
| Jul 7, 2026 | Opaleye Management Inc. 10% owner | Sale | 6,685 | $256.5K |
| Jul 7, 2026 | Opaleye Management Inc. 10% owner | Sale | 20,000 | $767.5K |
| Jul 6, 2026 | Opaleye Management Inc. 10% owner | Sale | 10,000 | $380.0K |
| Jul 2, 2026 | Opaleye Management Inc. 10% owner | Sale | 25,000 | $934.6K |
| Jul 2, 2026 | Opaleye Management Inc. 10% owner | Sale | 65,000 | $2.43M |
| Jun 17, 2026 | Adams Jennifer McKie Director | Option exercise | 50,000 | $189.0K |
| Jun 17, 2026 | Adams Jennifer McKie Director | Sale | 50,000 | $1.62M |
| May 28, 2026 | BRYNJELSEN SEAN President & CEO | Sale | 148 | $4.8K |
| May 28, 2026 | BRYNJELSEN SEAN President & CEO | Sale | 119,852 | $3.82M |
| May 27, 2026 | Krempa David Chief Business Officer | Option exercise | 12,476 | $17.1K |
| May 27, 2026 | Krempa David Chief Business Officer | Option exercise | 7,203 | $25.8K |
| May 27, 2026 | Krempa David Chief Business Officer | Sale | 19,679 | $619.4K |
| May 26, 2026 | Krempa David Chief Business Officer | Option exercise | 12,524 | $17.2K |
| May 26, 2026 | Krempa David Chief Business Officer | Option exercise | 25,000 | $34.5K |
| May 26, 2026 | Krempa David Chief Business Officer | Sale | 37,524 | $1.18M |
| May 22, 2026 | Krempa David Chief Business Officer | Sale | 519 | $18.2K |
| May 22, 2026 | Krempa David Chief Business Officer | Sale | 32,963 | $1.10M |
| May 22, 2026 | Krempa David Chief Business Officer | Option exercise | 30,591 | $109.5K |
| May 22, 2026 | Krempa David Chief Business Officer | Sale | 9,315 | $315.6K |
| Apr 21, 2026 | RIEDEL NORBERT G Director | Option exercise | 12,500 | $91.4K |
| Apr 21, 2026 | RIEDEL NORBERT G Director | Option exercise | 19,655 | $169.2K |
| Feb 3, 2026 | RIEDEL NORBERT G Director | Option exercised | 30,000 | $132.6K |
| Jan 14, 2026 | Gruber James R. Chief Financial Officer | Tax withheld | 2,293 | $35.5K |
| Jan 14, 2026 | Krempa David Chief Business Officer | Tax withheld | 1,942 | $30.3K |
| Jan 1, 2026 | BRYNJELSEN SEAN President & CEO | Tax withheld | 5,015 | $77.2K |
| Dec 12, 2025 | BRYNJELSEN SEAN President & CEO | Tax withheld | 6,732 | $113.3K |
| Dec 12, 2025 | Gruber James R. Chief Financial Officer | Tax withheld | 4,542 | $77.2K |
| Dec 12, 2025 | Krempa David Chief Business Officer | Tax withheld | 6,264 | $106.5K |
| Dec 12, 2025 | Erdogan-Trinkaus Ipek Chief Commercial Officer | Tax withheld | 85 | $1.4K |
| Aug 20, 2025 | Gruber James R. Chief Financial Officer | Sale | 2,631 | $42.1K |
| Aug 19, 2025 | Gruber James R. Chief Financial Officer | Sale | 39,082 | $631.6K |
| Jun 16, 2025 | Krempa David Chief Business Officer | Sale | 10,223 | $150.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Eton Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Eton Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading